PURPOSE: The purpose of this study was to determine the cardiac safety of pegylated liposomal doxorubicin (PLD) in patients receiving high cumulative doses of PLD. MATERIALS AND METHODS: A retrospective chart review of women with gynecologic malignancies treated at Roswell Park Cancer Institute from 2002 through 2007 who received cumulative doses of PLD >or=400 mg/m(2) was performed. RESULTS: Forty-two of 116 patients met the inclusion criteria. The mean age at initiation of PLD therapy was 63 years. The mean cumulative dose of PLD was 663.9 mg/m(2) (range 400-1,524 mg/m(2)). The mean cumulative number of cycles of PLD given was 9.8 (range 5-25). Multigated acquisition (MUGA) scans were obtained in 93% (39/42) of patients prior to or immediately following their first dose of PLD. The mean baseline ejection fraction was 63% (range 49-76%). Follow-up MUGA scans were performed on 7 patients (17%). Two of these patients had a decrease in their ejection fraction, but of only 3 and 1%. The remaining 5 patients who had follow-up MUGA scans had an average increase in their left ventricular ejection fraction of 4% (range 1-9%). No patients developed clinical evidence of congestive heart failure while being treated with PLD. There were no treatment interruptions or discontinuations due to cardiac toxicity. CONCLUSION: Cumulative doses of PLD >or=400 mg/m(2) are not associated with clinically evident cardiac toxicity in gynecologic oncology patients. (c) 2010 S. Karger AG, Basel.
PURPOSE: The purpose of this study was to determine the cardiac safety of pegylated liposomal doxorubicin (PLD) in patients receiving high cumulative doses of PLD. MATERIALS AND METHODS: A retrospective chart review of women with gynecologic malignancies treated at Roswell Park Cancer Institute from 2002 through 2007 who received cumulative doses of PLD >or=400 mg/m(2) was performed. RESULTS: Forty-two of 116 patients met the inclusion criteria. The mean age at initiation of PLD therapy was 63 years. The mean cumulative dose of PLD was 663.9 mg/m(2) (range 400-1,524 mg/m(2)). The mean cumulative number of cycles of PLD given was 9.8 (range 5-25). Multigated acquisition (MUGA) scans were obtained in 93% (39/42) of patients prior to or immediately following their first dose of PLD. The mean baseline ejection fraction was 63% (range 49-76%). Follow-up MUGA scans were performed on 7 patients (17%). Two of these patients had a decrease in their ejection fraction, but of only 3 and 1%. The remaining 5 patients who had follow-up MUGA scans had an average increase in their left ventricular ejection fraction of 4% (range 1-9%). No patients developed clinical evidence of congestive heart failure while being treated with PLD. There were no treatment interruptions or discontinuations due to cardiac toxicity. CONCLUSION: Cumulative doses of PLD >or=400 mg/m(2) are not associated with clinically evident cardiac toxicity in gynecologic oncology patients. (c) 2010 S. Karger AG, Basel.
Authors: F M Muggia; J D Hainsworth; S Jeffers; P Miller; S Groshen; M Tan; L Roman; B Uziely; L Muderspach; A Garcia; A Burnett; F A Greco; C P Morrow; L J Paradiso; L J Liang Journal: J Clin Oncol Date: 1997-03 Impact factor: 44.544
Authors: J Tate Thigpen; Carol A Aghajanian; David S Alberts; Susana M Campos; Alan N Gordon; Maurie Markman; D Scott McMeekin; Bradley J Monk; Peter G Rose Journal: Gynecol Oncol Date: 2005-01 Impact factor: 5.482
Authors: A N Gordon; C O Granai; P G Rose; J Hainsworth; A Lopez; C Weissman; R Rosales; T Sharpington Journal: J Clin Oncol Date: 2000-09 Impact factor: 44.544
Authors: M E R O'Brien; N Wigler; M Inbar; R Rosso; E Grischke; A Santoro; R Catane; D G Kieback; P Tomczak; S P Ackland; F Orlandi; L Mellars; L Alland; C Tendler Journal: Ann Oncol Date: 2004-03 Impact factor: 32.976
Authors: R G Schwartz; W B McKenzie; J Alexander; P Sager; A D'Souza; A Manatunga; P E Schwartz; H J Berger; J Setaro; L Surkin Journal: Am J Med Date: 1987-06 Impact factor: 4.965
Authors: Siang Hui Lim; Liangxing Wu; Lik Voon Kiew; Lip Yong Chung; Kevin Burgess; Hong Boon Lee Journal: PLoS One Date: 2014-03-12 Impact factor: 3.240